Recent research published in the journal Criminology indicates that adults currently using GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), report a weaker association between impulsivity and violent behavior compared to former users. While these findings suggest a potential behavioral benefit beyond weight loss and glycemic control, researchers emphasize that the study is observational and does not establish a direct causal link between the medication and a reduction in violence.
How GLP-1 Medications May Influence Behavior
The study, led by researchers at Rutgers University, analyzed data from a 2025 survey of 7,521 U.S. adults. By isolating a sample of 821 individuals who had used GLP-1 medications, the team examined the interplay between impulsive traits, alcohol consumption, and self-reported violent actions, including fighting or assault.
According to the authors, the correlation between impulsivity and violent behavior was approximately 62% lower among current medication users than among those who had discontinued use. Researchers posit that these drugs may function similarly to cognitive behavioral therapy by creating a neurological buffer that delays the transition from impulsive thought to physical action.
The Role of Alcohol and Impulse Control
Alcohol consumption is a well-documented risk factor for impulsive and aggressive behavior. The Rutgers study found that the link between alcohol intake and violent behavior was about 52% weaker in current GLP-1 users. This aligns with emerging clinical interest in how GLP-1 agonists interact with the brain’s reward system, particularly in the mesolimbic dopamine pathway, which governs cravings and addictive behaviors.
However, the study authors note that the results regarding alcohol were less consistent across various sensitivity analyses. While the biological mechanism remains a subject of ongoing investigation, the findings suggest that the medication’s impact on neurobiology may extend to the regulation of impulses that typically lead to substance-related aggression.
Why Observational Data Requires Caution
Because the research is cross-sectional, it captures a “snapshot” of data rather than tracking individuals over time. This design prevents the study from proving that the medication causes a reduction in violence. Other factors, such as improvements in overall health, mood, or socioeconomic status resulting from weight loss, could potentially influence these behavioral outcomes.
Daniel Semenza, lead author and director of research at the New Jersey Gun Violence Research Center, stated that while the association is notable, future longitudinal and experimental studies are necessary to confirm these effects. These upcoming trials will be essential to determine whether the observed behavioral changes are a direct pharmacological byproduct or an indirect result of the drug’s physiological impact on the body.
Key Findings at a Glance
- Study Scope: Data analyzed from 7,521 U.S. adults, with a specific focus on 821 current or former GLP-1 users.
- Impulsivity Link: The connection between impulsive traits and violence was 62% weaker in current users.
- Alcohol Consumption: The association between alcohol use and violent behavior was 52% lower in the current user group.
- Research Limitation: The study is observational and cannot confirm that GLP-1 drugs directly cause a decrease in violent behavior.
As GLP-1 prescriptions continue to rise, medical professionals are monitoring a broader range of outcomes. While the initial data from Rutgers provides a compelling starting point for behavioral research, patients should continue to follow guidance from their primary care physicians regarding the established metabolic uses of these medications.